topic

1225 Tri-signal polymeric artificial antigen presenting cells for cancer immunotherapy
Sydney R Shannon, Zoe Hsieh, Jordan Green, Jonathan Schneck

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1352; DOI: 10.1136/jitc-2023-SITC2023.1225
1227 Oral inulin gel formulation modulates the gut microbiome and improves the safety and efficacy of immune checkpoint blockers
Jin Xu, Kai Han, Xuehui Huang, James J Moon

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1354; DOI: 10.1136/jitc-2023-SITC2023.1227
1228 Enhancing STING activation by cyclic dinucleotide-manganese particles for systemic cancer immunotherapy
Xingwu Zhou, Xiaoqi Sun, Wang Gong, Ziye Wan, Yu Leo Lei, James J Moon

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1355; DOI: 10.1136/jitc-2023-SITC2023.1228
1229 Pre-treatment plasma proteomics-based predictive biomarkers for immune related adverse events in non-small cell lung cancer
Jarushka Naidoo, Niels Reinmuth, Igor Puzanov, Jair Bar, Iris Kamer, Ina Koch, Mor Moskovitz, Adva Levy-Barda, Abed Agbarya, Alona Zer, Mahmoud Abu-Amna, David Farrugia, Michal Lotem, Gillian Price, Tatiana Harkovsky, Adam Hassani, Rivka Katzenelson, Anirban Chatterjee, Ben Yelin, Itamar Sela, Adam Dicker, Yehonatan Elon, Michal Harel, Raya Leibowitz

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1356; DOI: 10.1136/jitc-2023-SITC2023.1229
1230 Novel imaging-based radiomics distinguishes radiation and immunotherapy induced pneumonitis in locally advanced NSCLC
Lukas Delasos, Mohammadhadi Khorrami, Vidya Viswanathan, Nathan Pennell, Anant Madabhushi, Pradnya Patil

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1357; DOI: 10.1136/jitc-2023-SITC2023.1230
1231 Exploring the landscape of pan-cancer immune-related adverse events through clinical trials big data mining
Muhammad Z Fadlullah Wilmot, Aik Choon Tan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1358; DOI: 10.1136/jitc-2023-SITC2023.1231
1232 PBMC humanized mouse model with clinical relevance in assessing the safety profile of 4–1BB agonist, urelumab, in 5 donors
Destanie Rose, Jiwon Yang, James G Keck, Li-Chin Yao

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1359; DOI: 10.1136/jitc-2023-SITC2023.1232
1233 Impact of infections occurring in patients receiving immune checkpoint inhibitors for renal cell carcinoma (RCC)
Catherine Wiechmann, Kelly Gee, Ethan Burns, Jiaqiong Xu, Yuqi Zhang, Aubrey Crenshaw, Abdullah Esmail, Ryan Kieser, Godsfavour Umoru, Ibrahim Muhsen, Kai Sun, Zimu Gong, Shivan Shah, Monisha Singh, Jun Zhang, Eleni Efstathiou, Maen Abdelrahim

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1360; DOI: 10.1136/jitc-2023-SITC2023.1233
1234 Impact of infections in patients receiving immune checkpoint inhibitor therapies for non-small cell lung cancer (NSCLC)
Kelly Gee, Catherine Wiechmann, Ethan Burns, Jiaqiong Xu, Yuqi Zhang, Abdullah Esmail, Aubrey Crenshaw, Ryan Kieser, Godsfavour Umoru, Ibrahim Muhsen, Kai Sun, Zimu Gong, Shivan Shah, Monisha Singh, Jun Zhang, Eric Bernicker, Maen Abdelrahim

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1361; DOI: 10.1136/jitc-2023-SITC2023.1234
1235 Safety of Immune checkpoint inhibitors in elderly patients over 75 years
Muhammad Awidi, Ahmed Al-Alwan, Mostafa Aglan, Muhammad Junaid Tariq

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1362; DOI: 10.1136/jitc-2023-SITC2023.1235

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages